35.75
+3.17%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About TCI Gene
Its shares trade on Taipei Exchange under the ticker 6879.TWO. It has been listed since 25 January 2022. In the fiscal year to 31 December 2025, it reported revenue of TWD 273.6m and net income of TWD 40.6m. At that date it held total assets of TWD 1.01bn and shareholders' equity of TWD 890.5m.
TCI GENE, Inc. engages in provision of health management services. The company is headquartered in Taipei City, Taipei. The company went IPO on 2022-01-25. The main products include genetic testing services, virus testing services, cell experiment services, production of adipose-derived stem cell preparations for the treatment of degenerative arthritis and knee cartilage defects, production of natural killer cell preparations for the treatment of solid cancer, and personalized genetic health food. Genetic testing technology is mainly in the field of disease risk and drug genetic testing, including comprehensive genetic testing, child growth and development genetic testing, youth beauty genetic testing, weight management genetic testing, anti-aging genetic testing, cardiovascular drug genetic testing and depression/insomnia Pharmacogenetic testing. The firm's products are mainly sold in Taiwan.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 25 Jan 2022
- Website
- genext.me ↗
Leadership
Pay as last reported
- Mr. Yung-Hsiang LinChairman of the Board, since 2012
- Jilun WuGeneral Manager
- Ms. Chen-Chen FuHead of Global Finance and Accounting Center, Director, since 2021
- Junwei LinHead of Accounting
- Counde O'YangDirector
- Houng-Pei YangDirector
- Ko-yin ChangIndependent Director
- Mr. Shui-Yung LinIndependent Director
- Mr. Wei-Hsin SunIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Genetic testing services are a key product in Taiwan's health care sector.
- Adipose-derived stem cell preparations treat degenerative arthritis and knee cartilage defects.
- Personalized genetic health food is a unique offering in the market.
Weaknesses
- Virus testing services face competition from established health care providers in Taiwan.
- Cell experiment services are limited to internal use within the company.
- Production of natural killer cell preparations is restricted to solid cancer treatments.
Opportunities
- Expansion into new health care segments like anti-aging genetic testing in Taiwan.
- Growth in demand for personalized genetic health food across Taiwan.
- Increasing adoption of comprehensive genetic testing services in Taiwan.
Threats
- Regulatory changes in Taiwan's health care industry could impact operations.
- Competition from other health care companies in Taiwan's market.
- Economic downturns in Taiwan may reduce consumer spending on health services.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.